Amyloid-beta-directed antibodies are used to treat Alzheimer's disease, particular those with mild cognitive impairment or early-stage dementia. These medications work by targeting and removing amyloid-beta plaques in the brain, which are believed to contribute to the progression of the condition. Amyloid-beta-directed antibodies are typically administered as injections. Examples include lecanemab (Leqembi) and donanemab (Kisunla). These treatments aim to slow the progression of cognitive decline.
